Safety of Once-Weekly Dapsone for Pneumocystis jirovecii Pneumonia Prophylaxis in Kidney Transplant Recipients

被引：0

作者：

Schumacher, Lauren ^{[1
]}

Philippart, Olivia ^{[1
]}

Carr, Abbey ^{[2
]}

Sadler, Catherine J. ^{[2
]}

Paluri, Sravanthi ^{[3
]}

机构：

[1] Univ Kentucky HealthCare, Dept Pharm, Lexington, KY 40536 USA

[2] Univ Kentucky, Coll Pharm, Lexington, KY USA

[3] Univ Kentucky HealthCare, Dept Nephrol, Div Transplant, Lexington, KY USA

来源：

TRANSPLANT INFECTIOUS DISEASE | 2025年

关键词：

anemia; dapsone; neutropenia; PJP prophylaxis; sulfamethoxazole-trimethoprim; CARINII-PNEUMONIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; HEMOLYTIC-ANEMIA; RANDOMIZED-TRIAL; PYRIMETHAMINE; NEUTROPENIA; COTRIMOXAZOLE; PREVENTION; COMPLICATIONS;

D O I：

10.1111/tid.70012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Sulfamethoxazole-trimethoprim (SMX-TMP) is recommended first-line for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in kidney transplant recipients. In cases of sulfa allergy or intolerance, our center utilizes dapsone 100 mg once weekly as alternative prophylaxis. As both agents have the potential to cause hematologic abnormalities, we sought to compare hematologic effect profiles of weekly dapsone versus SMX-TMP in kidney transplant recipients. Methods: This retrospective, single-center, cohort study included kidney transplant recipients who received SMX-TMP or dapsone for PJP prophylaxis. The primary endpoint was the change in hemoglobin from baseline to nadir. Secondary endpoints included hemoglobin and white blood cell (WBC) count at 1, 3, and 6 months posttransplant, time to hemoglobin nadir, neutropenia incidence, and ANC nadir. In addition, we evaluated the incidence of hospital readmission, bacteremia, and PJP. Results: A total of 509 kidney transplant recipients were included (334 SMX-TMP vs. 175 dapsone). Median decrease in hemoglobin (g/dL) from baseline to nadir was greater in the dapsone group (0 SMX-TMP vs. -0.20 dapsone; p = 0.046). Mean absolute hemoglobin count was lower in the dapsone group at all time points. There was no difference in WBC, ANC nadir, or incidence of neutropenia at any time point between groups. Greater frequencies in readmissions (30.7% vs. 55.7%; p < 0.001) and bacteremia (3.6% vs. 10.8%; p < 0.001) were observed in the dapsone arm. Conclusions: Once-weekly dapsone is associated with statistically significant decreases in hemoglobin when compared to SMX-TMP in a kidney transplant cohort, which may be clinically relevant in select patients. Dapsone use may also increase infection risk. image

引用

页数：9

共 55 条

[1]

Fishman J.A., Gans H., Pneumocystis jiroveci in Solid Organ Transplantation: Guidelines From the American Society of Transplantation Infectious Diseases Community of Practice, Clinical Transplantation, 33, 9, (2019)

[2]

Opravil M., Joos B., Luthy R., Levels of Dapsone and Pyrimethamine in Serum During Once-Weekly Dosing for Prophylaxis of Pneumocystis carinii Pneumonia and Toxoplasmic Encephalitis, Antimicrobial Agents and Chemotherapy, 38, 5, pp. 1197-1199, (1994)

[3]

Falloon J., Lavelle J., Ogata-Arakaki D., Et al., Pharmacokinetics and Safety of Weekly Dapsone and Dapsone Plus Pyrimethamine for Prevention of Pneumocystis Pneumonia, Antimicrobial Agents and Chemotherapy, 38, 7, pp. 1580-1587, (1994)

[4]

Evans R.A., Clifford T.M., Tang S., Au T., Fugit A.M., Efficacy of Once-Weekly Dapsone Dosing for Pneumocystis jirovecii Pneumonia Prophylaxis Post Transplantation, Transplant Infectious Disease, 17, 6, pp. 816-821, (2015)

[5]

Lum J., Echenique I., Athans V., Koval C.E., Alternative Pneumocystis Prophylaxis in Solid Organ Transplant Recipients at Two Large Transplant Centers, Transplant Infectious Disease, 23, 1, (2021)

[6]

Bamgbola O.F., Spectrum of Anemia After Kidney Transplantation: Pathophysiology and Therapeutic Implications, Clinical Transplantation, 30, 10, pp. 1185-1194, (2016)

[7]

Zafrani L., Truffaut L., Kreis H., Et al., Incidence, Risk Factors and Clinical Consequences of Neutropenia Following Kidney Transplantation: A Retrospective Study, American Journal of Transplantation, 9, 8, pp. 1816-1825, (2009)

[8]

Hedvat J., Poladi N., Salerno D.M., Dube G.K., Lange N.W., An Evaluation of PJP Prophylaxis and Anemia Among Renal Transplant Recipients, Transplant Infectious Disease, 23, 3, (2021)

[9]

Lor K.W., Kransdorf E.P., Patel J.K., Chang D.H., Kobashigawa J.A., Kittleson M.M., Dapsone-Associated Anemia in Heart Transplant Recipients With Normal Glucose-6-Phosphate Dehydrogenase Activity, Journal of Clinical Medicine, 11, 21, (2022)

[10]

Khatri A., Lal M.R.S., Bhaskaran M.C., Dapsone-Associated Hemolytic Anemia in Renal Transplant Recipients With Normal Glucose-6-Phosphate-Dehydrogenase Levels, American Journal of Therapeutics, 29, 3, pp. e369-e372, (2022)

← 1 2 3 4 5 6 →